Farag Kameel D. reported grant involving 1,728 shares of Akari Therapeutics Plc at $7.52 for $13.0k on Aug 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Interim CFO
Interim CFO
Filed Aug 19, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$12,994.56Shares × reported price
Shares traded
1,728American Depositary Shares representing Ordinary Shares
Price per share
$7.52Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
23,309Direct
Trade date
Aug 17, 2026Grant
Filed
Aug 19, 2026, 5:00 PM ET2-day reporting delay
Accession
0001493152-26-039246Code A · Transaction 11477
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

AKTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AKTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +39%1w ago −4.7%1d ago −4.6%
Returns since7d +15%30d +25%90d180d1y

Footnotes in full

F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on September 15, 2026.